ClearPoint Neuro, Inc. (NASDAQ:CLPT) Shares Sold by Legato Capital Management LLC

Legato Capital Management LLC lowered its holdings in ClearPoint Neuro, Inc. (NASDAQ:CLPT) by 23.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 122,057 shares of the company’s stock after selling 36,911 shares during the period. Legato Capital Management LLC owned approximately 0.44% of ClearPoint Neuro worth $1,877,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. R Squared Ltd purchased a new position in shares of ClearPoint Neuro in the fourth quarter valued at $32,000. Barclays PLC boosted its stake in shares of ClearPoint Neuro by 24.3% in the third quarter. Barclays PLC now owns 5,674 shares of the company’s stock valued at $64,000 after purchasing an additional 1,109 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of ClearPoint Neuro by 58.7% in the third quarter. JPMorgan Chase & Co. now owns 9,770 shares of the company’s stock valued at $110,000 after purchasing an additional 3,612 shares during the period. Verition Fund Management LLC purchased a new position in shares of ClearPoint Neuro in the third quarter valued at $123,000. Finally, Oppenheimer & Co. Inc. purchased a new position in shares of ClearPoint Neuro in the third quarter valued at $156,000. 30.08% of the stock is currently owned by hedge funds and other institutional investors.

ClearPoint Neuro Trading Down 2.3 %

NASDAQ CLPT opened at $17.75 on Wednesday. ClearPoint Neuro, Inc. has a 12 month low of $5.11 and a 12 month high of $19.22. The company’s fifty day moving average price is $16.10 and its two-hundred day moving average price is $13.05.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. B. Riley upped their target price on shares of ClearPoint Neuro from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Tuesday, January 28th. Lake Street Capital increased their price objective on shares of ClearPoint Neuro from $17.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, January 21st.

About ClearPoint Neuro

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.